<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Incyte Corporation

    Incyte Corporation

    Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focus...

    Incyte Corporation is a Wilmington, Delaware-ba...

    Filing Type:    PU
    dna ID, Inc.

    dna ID, Inc.

    The DNA ID platform is a community marketplace for genomics research. The app allo...

    The DNA ID platform is a community marketplace ...

    Amount Raised:    $57,589.00
    Fundraising Status:    EC
    Filing Type:    CF
    Delee Corp

    Delee Corp

    At Delee we’re fundamentally changing not only the way cancer is detected but also...

    At Delee we’re fundamentally changing not only ...

    Amount Raised:    $492,503.00
    Fundraising Status:    EC
    Filing Type:    CF
    Lonza Group AG

    Lonza Group AG

    Lonza is an integrated solutions provider that creates value along the Healthcare ...

    Lonza is an integrated solutions provider that ...

    Filing Type:    PU
    Savara, Inc.

    Savara, Inc.

    Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex,...

    Savara is an orphan lung disease company. Savar...

    Filing Type:    PU
    Kala Pharmaceuticals, Inc.

    Kala Pharmaceuticals, Inc.

    Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the de...

    Kala Pharmaceuticals, Inc. (Kala) is a biopharm...

    Filing Type:    PU
    Trillium Therapeutics Inc.

    Trillium Therapeutics Inc.

    Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...

    Trillium Therapeutics Inc. is a clinical stage ...

    Filing Type:    PU
    Nektar Therapeutics

    Nektar Therapeutics

    Nektar Therapeutics is a research-based development stage biopharmaceutical compan...

    Nektar Therapeutics is a research-based develop...

    Filing Type:    PU
    Halozyme Therapeutics, Inc.

    Halozyme Therapeutics, Inc.

    Halozyme is a clinical-stage biotechnology company focused on developing and comme...

    Halozyme is a clinical-stage biotechnology comp...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.